Biotechnology: A sector built around practical scientific innovation

Genflow Biosciences Plc

Biotechnology uses living organisms, cells and biological processes to create products and solve practical problems. This is a sector where scientific progress can become commercial opportunity across healthcare, agriculture, industry and environmental applications.

At its simplest, biotechnology applies biology to product development. This can include using microorganisms to produce medicines, improving crops through genetic techniques, developing diagnostic tools, or creating cleaner industrial processes. The common thread is the use of biological systems to improve how products are made, how diseases are treated, or how resources are managed.

Healthcare is one of the most visible areas of biotechnology. Companies in this space may work on new medicines, vaccines, gene therapies or diagnostic tests. These products can address clear market needs, particularly where existing treatments are limited.

Biotechnology also has relevance beyond medicine. In agriculture, it can help improve crop performance, increase resistance to pests and support more efficient food production. In industrial settings, biological processes can be used to make chemicals, materials and fuels in ways that may reduce waste or environmental impact.

Genflow Biosciences plc (LON:GENF, OTCQB:GENFF, FRA:WQ5) is a UK-based biotech firm with R&D facilities in Belgium focused on developing novel therapeutic approaches that potentially halt or slow the aging process in humans and dogs supporting longer, healthier lives

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Healthspan becomes a bigger part of the healthy ageing debate

Healthspan is becoming a key part of the longevity discussion as attention shifts from simply living longer to staying healthier for more of those years.

Genflow nears key data readout for SIRT6 gene therapy platform

Genflow is nearing a key data point as it combines animal study results, specialist RNA delivery support and broader patent protection.

Genflow Biosciences links ageing science with MASH research

MASH gives Genflow Biosciences a defined opportunity to explore how its SIRT6-based gene therapy research could address metabolic liver damage, inflammation and fibrosis.

Genflow Biosciences advances SIRT6 patent portfolio in US and Europe

Genflow Biosciences has reported progress on its SIRT6 patent families, including a published US application and Track One examination.

Genflow Biosciences moves longevity programme towards its next test

Genflow Biosciences has reported better survival rates and no adverse events three months into its ageing-dog gene therapy study.

Genflow Biosciences advances a focused gene therapy pipeline for healthy ageing

Genflow Biosciences is building a focused SIRT6 gene therapy pipeline across human health, veterinary medicine and skin-related applications.

Search